COMPANY
Dexcom
FDA-cleared device company Clinical Phase 3
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| QC Inspector 3 - Morning Shift | Athenry, Ireland | Oct 23, 2026 | Oct 14, 2026 |
| Sr Staff Forecast Analyst | Manila, Philippines | Oct 23, 2026 | Oct 23, 2026 |
| Customer Advocacy Generalist | Vilnius, Lithuania | Oct 23, 2026 | Oct 23, 2026 |
| Sr Enterprise Privacy Analyst, Maternity Cover | Vilnius, Lithuania | Oct 22, 2026 | Oct 12, 2026 |
| Sr Quality Assurance Analyst | 2 locations (listed on the posting) | Oct 22, 2026 | Oct 20, 2026 |
Timeline
- FDA FDA 510(k) clearance: Stelo Glucose Biosensor System — K262472, Aug 11, 2026. Applicant at approval: Dexcom, Inc. source ↗
- Trial start —: Global Long-term Outcomes and Real-World Evaluation of Dexcom Continuous Glucose Monitoring System (Dexcom GLOW) source ↗
- FDA FDA 510(k) clearance: Stelo Glucose Biosensor System — K260935, Jun 12, 2026. Applicant at approval: Dexcom, Inc. source ↗
- FDA FDA 510(k) clearance: Dexcom G7 Continuous Glucose Monitoring System;Dexcom G7 15 Day Continuous Glucose Monitoring System — K261402, Jun 8, 2026. Applicant at approval: Dexcom, Inc. source ↗
- FDA FDA 510(k) clearance: Stelo Glucose Biosensor System — K261359, May 21, 2026. Applicant at approval: Dexcom, Inc. source ↗
- FDA FDA 510(k) clearance: Dexcom G7 Continuous Glucose Monitoring (CGM) System; Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System — K253737, Feb 3, 2026. Applicant at approval: Dexcom, Inc. source ↗
- FDA FDA 510(k) clearance: Dexcom G7 Continuous Glucose Monitoring (CGM) System, Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System — K253710, Dec 17, 2025. Applicant at approval: Dexcom, Inc. source ↗
- Trial start Phase 4: Continuous Glucose Monitoring By DExcom iN PEople Followed for Type 2 DIabeTes on Insulin Therapy in the Kingdom of Saudi Arabia source ↗
- FDA FDA 510(k) clearance: Dexcom Smart Basal — K252818, Nov 18, 2025. Applicant at approval: Dexcom, Inc. source ↗
- FDA FDA 510(k) clearance: Dexcom G7 15 Day Continuous Glucose Monitoring System — K243214, Apr 9, 2025. Applicant at approval: Dexcom, Inc. source ↗
- Trial start Not phased (device or behavioral study): CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on Insulin source ↗
- Trial start —: Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry) source ↗
- Trial start Phase 1: Evaluation of Basal Insulin Initialization and Titration in People With Type 2 Diabetes Wearing a Dexcom G6 Sensor source ↗
- Trial start Not phased (device or behavioral study): Remote Monitoring of Vital Signs With Telehealth to Prevent Readmissions for Dysglycemia source ↗
- Trial start —: Performance of the Dexcom Continuous Glucose Monitoring (CGM) System in Pregnant Women With Diabetes Mellitus source ↗
- Trial start Not phased (device or behavioral study): Effectiveness and Safety of the Dexcom G6 Continuous Glucose Monitoring System in Non-Critically Ill Patients in the Inpatient Setting source ↗
- Trial start Not phased (device or behavioral study): Evaluation of the Safety and Effectiveness of the Dexcom Continuous Glucose Monitoring (CGM) System source ↗
- Trial start —: Evaluation of Modified Adhesives With Dexcom G6 Sensor source ↗
- Trial start Not phased (device or behavioral study): Evaluation of the Safety and Effectiveness of the Dexcom Glucose Monitoring (CGM) System source ↗
- Trial start Not phased (device or behavioral study): Assessing Non-adjunctive CGM Safety at Home and in New Markets source ↗
- Trial start —: Prediabetes and Type 2 Diabetes Data Collection Study source ↗
- Trial start —: Performance of the Dexcom G6 Continuous Glucose Monitoring (CGM) System in Pregnant Women With Diabetes Mellitus source ↗
- Trial start —: Glucose Risk Assessment in Employer Populations source ↗
- Trial start Not phased (device or behavioral study): Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) source ↗
- Trial start Not phased (device or behavioral study): Type 2 Diabetes (T2D) Basal Insulin Users: The Mobile Study (MOBILE) source ↗
Upcoming milestones
- Nov 2, 2026 (ESTIMATED) · Phase 4 · Continuous Glucose Monitoring By DExcom iN PEople Followed for Type 2 DIabeTes on Insulin Therapy in the Kingdom of Saudi Arabia · NCT07603284
- Mar 31, 2028 (ESTIMATED) · · Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry) · NCT06483945
- May 1, 2030 (ESTIMATED) · · Global Long-term Outcomes and Real-World Evaluation of Dexcom Continuous Glucose Monitoring System (Dexcom GLOW) · NCT07681024
Clinical trials (lead sponsor) 35
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06483945 | Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry) | Not listed | Active, not recruiting | Feb 28, 2024 | Mar 31, 2028 (estimated) |
| NCT06601166 | CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on Insulin | Not phased (device or behavioral study) | Active, not recruiting | Aug 15, 2024 | May 13, 2026 (actual) |
| NCT07681024 | Global Long-term Outcomes and Real-World Evaluation of Dexcom Continuous Glucose Monitoring System (Dexcom GLOW) | Not listed | Not yet recruiting | Jun 15, 2026 | May 1, 2030 (estimated) |
| NCT07681375 | Evaluation of Basal Insulin Initialization and Titration in People With Type 2 Diabetes Wearing a Dexcom G6 Sensor | Phase 1 | Active, not recruiting | Apr 11, 2023 | Jan 16, 2026 (actual) |
| NCT07603284 | Continuous Glucose Monitoring By DExcom iN PEople Followed for Type 2 DIabeTes on Insulin Therapy in the Kingdom of Saudi Arabia | Phase 4 | Active, not recruiting | Nov 24, 2025 | Nov 2, 2026 (estimated) |
| NCT05746286 | Remote Monitoring of Vital Signs With Telehealth to Prevent Readmissions for Dysglycemia | Not phased (device or behavioral study) | Completed | Feb 1, 2023 | Nov 29, 2023 (actual) |
| NCT04529824 | Glucose Risk Assessment in Employer Populations | Not listed | Completed | Apr 1, 2019 | Jul 22, 2019 (actual) |
| NCT04585139 | Assessing Non-adjunctive CGM Safety at Home and in New Markets | Not phased (device or behavioral study) | Completed | Oct 6, 2020 | Feb 7, 2022 (actual) |
| NCT04905628 | Performance of the Dexcom Continuous Glucose Monitoring (CGM) System in Pregnant Women With Diabetes Mellitus | Not listed | Unknown status (ClinicalTrials.gov) | Jul 8, 2021 | Mar 31, 2022 (estimated) |
| NCT04794478 | Evaluation of the Safety and Effectiveness of the Dexcom Continuous Glucose Monitoring (CGM) System | Not phased (device or behavioral study) | Completed | Feb 19, 2021 | Aug 9, 2021 (actual) |
| NCT04503239 | Prediabetes and Type 2 Diabetes Data Collection Study | Not listed | Unknown status (ClinicalTrials.gov) | Jul 22, 2020 | Feb 27, 2022 (estimated) |
| NCT03340831 | Continuous Monitoring and Control of Hypoglycemia | Not listed | Unknown status (ClinicalTrials.gov) | Oct 20, 2017 | Dec 30, 2023 (estimated) |
| NCT04879693 | Effectiveness and Safety of the Dexcom G6 Continuous Glucose Monitoring System in Non-Critically Ill Patients in the Inpatient Setting | Not phased (device or behavioral study) | Unknown status (ClinicalTrials.gov) | 2021-06 | 2021-12 (estimated) |
| NCT03566693 | Type 2 Diabetes (T2D) Basal Insulin Users: The Mobile Study (MOBILE) | Not phased (device or behavioral study) | Completed | Jul 30, 2018 | Jan 4, 2021 (actual) |
| NCT04840446 | Evaluation of Modified Adhesives With Dexcom G6 Sensor | Not listed | Completed | Feb 8, 2021 | Mar 16, 2021 (actual) |
| NCT03620357 | Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) | Not phased (device or behavioral study) | Completed | Sep 5, 2018 | May 27, 2020 (actual) |
| NCT04645641 | Evaluation of the Safety and Effectiveness of the Dexcom Glucose Monitoring (CGM) System | Not phased (device or behavioral study) | Unknown status (ClinicalTrials.gov) | Oct 12, 2020 | 2020-12 (estimated) |
| NCT03935191 | Performance of the Dexcom G6 Continuous Glucose Monitoring (CGM) System in Pregnant Women With Diabetes Mellitus | Not listed | Unknown status (ClinicalTrials.gov) | May 1, 2019 | May 31, 2019 (estimated) |
| NCT02880267 | Effectiveness and Safety of the Dexcom™ G6 Continuous Glucose Monitoring System | Not phased (device or behavioral study) | Completed | 2016-05 | 2017-07 (actual) |
| NCT03087877 | Evaluation of the Dexcom G6 Continuous Glucose Monitoring System With a Non-Interferent Sensor | Not phased (device or behavioral study) | Completed | Feb 3, 2017 | Mar 4, 2017 (actual) |
| NCT02087995 | Effectiveness and Safety Study of the Dexcom G4 Platinum With Modified Algorithm | Not phased (device or behavioral study) | Completed | 2013-12 | 2014-03 (actual) |
| NCT02363907 | Observational Study to Evaluate the Effectiveness and Safety of the Dexcom G4 Continuous Glucose Monitoring System in Pediatrics | Not listed | Completed | 2012-09 | 2012-10 (actual) |
| NCT02282397 | Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes | Not phased (device or behavioral study) | Completed | 2014-09 | 2016-11 (actual) |
| NCT01111370 | Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose Monitoring System | Not phased (device or behavioral study) | Completed | 2010-02 | 2010-04 (actual) |
| NCT02696252 | G5® Mobile Continuous Glucose Monitoring System Automated vs. Manual Sensor Applicator | Not listed | Completed | 2016-01 | 2016-04 (actual) |
| NCT01514292 | Effectiveness and Safety Study of the Dexcom G4™ Continuous Glucose Monitoring System | Not phased (device or behavioral study) | Completed | 2011-12 | 2012-02 (actual) |
| NCT01627184 | Long-term Use: CGM System Assessment in Adult Athletes With Diabetes Mellitus | Not listed | Completed | 2012-05 | 2013-01 (actual) |
| NCT01627210 | Evaluation of Glycemic Control Using Adjunctive Continuous Glucose Monitoring With the Dexcom G4 System | Not listed | Completed | 2012-05 | 2012-12 (actual) |
| NCT01667185 | Effectiveness and Safety of the Dexcom™ G4 Continuous Glucose Monitoring System in Pediatric Subjects With Diabetes Mellitus | Not listed | Completed | 2012-07 | 2012-12 (actual) |
| NCT01514305 | Observational Study to Evaluate the Effectiveness and Safety Study of the Dexcom G4™ Continuous Glucose Monitoring System | Not listed | Completed | 2011-11 | 2011-12 (actual) |
| NCT01185496 | Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes Mellitus | Not listed | Completed | 2010-08 | 2010-10 (actual) |
| NCT01104142 | Efficacy of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes Mellitus on Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) Therapy | Not listed | Completed | 2009-04 | Not listed |
| NCT00925080 | Pivotal Study of the Intravenous Blood Glucose (IVBG) System, In-Clinic Setting | Not listed | Completed | 2009-06 | 2009-07 (actual) |
| NCT00939289 | Concurrent Use of Two Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes Mellitus (T1DM) | Not listed | Completed | 2008-07 | 2008-08 (actual) |
| NCT00722241 | Effectiveness and Safety Study of the Next-Generation DexCom™ SEVEN® Continuous Glucose Monitoring System | Not listed | Completed | 2008-05 | 2008-06 (actual) |
FDA records (last 2 years)
- FDA 510(k) clearance: Stelo Glucose Biosensor System — K262472, Aug 11, 2026. Applicant at approval: Dexcom, Inc. source ↗
- FDA 510(k) clearance: Stelo Glucose Biosensor System — K260935, Jun 12, 2026. Applicant at approval: Dexcom, Inc. source ↗
- FDA 510(k) clearance: Dexcom G7 Continuous Glucose Monitoring System;Dexcom G7 15 Day Continuous Glucose Monitoring System — K261402, Jun 8, 2026. Applicant at approval: Dexcom, Inc. source ↗
- FDA 510(k) clearance: Stelo Glucose Biosensor System — K261359, May 21, 2026. Applicant at approval: Dexcom, Inc. source ↗
- FDA 510(k) clearance: Dexcom G7 Continuous Glucose Monitoring (CGM) System; Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System — K253737, Feb 3, 2026. Applicant at approval: Dexcom, Inc. source ↗
- FDA 510(k) clearance: Dexcom G7 Continuous Glucose Monitoring (CGM) System, Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System — K253710, Dec 17, 2025. Applicant at approval: Dexcom, Inc. source ↗
- FDA 510(k) clearance: Dexcom Smart Basal — K252818, Nov 18, 2025. Applicant at approval: Dexcom, Inc. source ↗
- FDA 510(k) clearance: Dexcom G7 15 Day Continuous Glucose Monitoring System — K243214, Apr 9, 2025. Applicant at approval: Dexcom, Inc. source ↗
Open jobs 305
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| QC Inspector 3 - Morning Shift | Athenry, Ireland | Oct 23, 2026 | Oct 14, 2026 | Not stated |
| Sr Staff Forecast Analyst | Manila, Philippines | Oct 23, 2026 | Oct 23, 2026 | Not stated |
| Customer Advocacy Generalist | Vilnius, Lithuania | Oct 23, 2026 | Oct 23, 2026 | Not stated |
| Sr Enterprise Privacy Analyst, Maternity Cover | Vilnius, Lithuania | Oct 22, 2026 | Oct 12, 2026 | Senior |
| Sr Quality Assurance Analyst | 2 locations (listed on the posting) | Oct 22, 2026 | Oct 20, 2026 | Not stated |
| Oracle Fusion Financials Analyst – Edinburgh, UK | Remote - United Kingdom | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Senior Tax Accountant | Manila, Philippines | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Territory Business Manager, Southlake Texas | Bedford, Texas | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Hardware Engineer 2 | San Diego, California | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Manufacturing Technician 2-Monday-Friday (6:00AM-2:30PM) | San Diego, California | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Capability Leader - Fraud Management | 2 locations (listed on the posting) | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Sales Operations Analyst | Bracknell, United Kingdom | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Lab Technician III - Front End Day Shift | Athenry, Ireland | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Business Intelligence Analyst - Healthcare (m/w/d) | Mainz, Germany | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Team Lead Rechnungsstellung - Healthcare (m/w/d) - 1-jähriger befristeter Vertrag | Mainz, Germany | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Senior Business Analyst and Business Relationship Manager (E-commerce) | Bracknell | Oct 21, 2026 | Oct 12, 2026 | Senior |
| Inside Sales Representative – HCP Acquisition & Account Growth | Vancouver, British Columbia | Oct 21, 2026 | Oct 12, 2026 | Entry |
| Inside Sales Representative – Patient Acquisition & Account Growth | Remote British Columbia | Oct 21, 2026 | Oct 12, 2026 | Mid |
| Contract Administration Representative | Vilnius, Lithuania | Oct 21, 2026 | Oct 12, 2026 | Mid |
| Automation Technician (Weekend Day Shift) | Athenry, Ireland | Oct 21, 2026 | Oct 12, 2026 | Mid |
| Staff IT Business Systems Analyst- Strategic Initiatives | Remote - United States | Oct 21, 2026 | Oct 16, 2026 | Not stated |
| Engineering Technician 3 | Penang, Malaysia | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| Sr Trainer | Taguig, Philippines | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| Sr Trainer | Cebu, Philippines | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| Sr Business Process Analyst | 2 locations (listed on the posting) | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| District Business Manager - Northern Illinois & Wisconsin | Chicago, Illinois | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| Manufacturing Technician 2 ( Monday - Friday 6:00AM - 2:30 PM ) | San Diego, California | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Staff Algorithm Engineer - Advanced Sensing Algorithms | Remote California | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Senior Algorithm Engineer - Sensing Algorithms | Remote California | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Sr Paralegal | San Diego, California | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Lead Legal Counsel | San Diego, California | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Sr Manager - Application Automation | San Diego, California | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Territory Business Manager - Montreal East - Abitibi | Remote Quebec | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| IT Infrastructure Asset & Lifecycle Analyst | 2 locations (listed on the posting) | Oct 20, 2026 | Oct 12, 2026 | Senior |
| Enterprise Applications - Integration Support | 2 locations (listed on the posting) | Oct 20, 2026 | Oct 12, 2026 | Mid |
| Senior Commercial Forecasting Analyst – Barcelona, Spain | 3 locations (listed on the posting) | Oct 20, 2026 | Oct 12, 2026 | Senior |
| Customer Advocacy Generalist | Vilnius, Lithuania | Oct 20, 2026 | Oct 20, 2026 | Not stated |
| Medical Affairs Specialist (Maternity Cover) | Vilnius, Lithuania | Oct 20, 2026 | Oct 20, 2026 | Not stated |
| Staff Enterprise Capital Management Analyst | San Diego, California | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Process Development Engineer 2 | San Diego, California | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Customer Account Support Analyst | San Diego, California | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Document Control Specialist 3 - Evening Shift | Athenry, Ireland | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Executive Assistant, Chief People & Culture Officer | San Diego, California | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Production Operator - Days | Athenry, Ireland | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| QA Engineer 2 | Penang, Malaysia | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Manager Quality Assurance | Tokyo, Japan | Oct 19, 2026 | Oct 19, 2026 | Not stated |
| District Business Manager (Tampa, FL) | Tampa, Florida | Oct 19, 2026 | Oct 20, 2026 | Not stated |
| District Business Manager (Nashville, TN) | Nashville, Tennessee | Oct 19, 2026 | Oct 20, 2026 | Not stated |
| District Business Manager - Houston, TX | Houston, Texas | Oct 19, 2026 | Oct 20, 2026 | Not stated |
| District Business Manager - New Shore, NJ | Remote New Jersey | Oct 19, 2026 | Oct 20, 2026 | Not stated |
Connect
See your connections at Dexcom on LinkedIn (search by name, results not checked)